Loading...
XNASGHSI
Market cap4mUSD
Oct 30, Last price  
3.22USD
Name

Guardion Health Sciences Inc

Chart & Performance

D1W1MN
XNAS:GHSI chart
P/E
27.51
P/S
0.35
EPS
0.12
Div Yield, %
0.00%
Shrs. gr., 5y
76.64%
Rev. gr., 5y
67.03%
Revenues
12m
+10.85%
260,355164,582112,811141,029437,349942,153902,9371,889,8447,233,11711,049,77212,248,550
Net income
158k
P
-1,242,678-1,320,492-8,841,296-5,748,397-5,305,169-7,767,407-11,136,673-8,578,928-24,745,009-30,277,134158,033
CFO
-4m
L-41.32%
-506,299-543,378-1,139,758-1,653,574-3,403,696-4,173,831-6,030,004-8,013,929-10,644,416-7,446,812-4,369,885
Dividend
Sep 09, 20245 USD/sh
Earnings
Mar 27, 2025

Profile

Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
IPO date
Apr 05, 2019
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
12,249
10.85%
11,050
52.77%
7,233
282.74%
Cost of revenue
16,190
18,371
17,716
Unusual Expense (Income)
NOPBT
(3,942)
(7,321)
(10,483)
NOPBT Margin
Operating Taxes
15,355
673
Tax Rate
NOPAT
(3,942)
(22,676)
(11,156)
Net income
158
-100.52%
(30,277)
22.36%
(24,745)
188.44%
Dividends
Dividend yield
Proceeds from repurchase of equity
(5,250)
14,268
33,663
BB yield
77.36%
-8,772.02%
-10,980.11%
Debt
Debt current
4
22
Long-term debt
4
30
Deferred revenue
Other long-term liabilities
2,453
4,507
Net debt
(6,360)
(10,648)
(9,037)
Cash flow
Cash from operating activities
(4,370)
(7,447)
(10,644)
CAPEX
(4)
(6)
(75)
Cash from investing activities
16
4,990
(31,011)
Cash from financing activities
(5,192)
14,268
37,231
FCF
(6,408)
(22,470)
(12,430)
Balance
Cash
6,360
10,655
9,090
Long term investments
Excess cash
5,747
10,103
8,728
Stockholders' equity
(93,565)
(88,473)
(78,778)
Invested Capital
104,164
106,151
101,101
ROIC
ROCE
EV
Common stock shares outstanding
1,271
1,121
474
Price
5.34
3,580.22%
0.15
-77.58%
0.65
55.93%
Market cap
6,786
4,072.16%
163
-46.94%
307
1,454.53%
EV
427
(5,235)
(8,731)
EBITDA
(3,922)
(6,072)
(9,576)
EV/EBITDA
0.86
0.91
Interest
15,355
Interest/NOPBT